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esponsibility of Xi’Abstract The sample preparation of samples containing bovine serum albumin (BSA), e.g., as used in
transdermal Franz diffusion cell (FDC) solutions, was evaluated using an analytical quality-by-design (QbD)
approach. Traditional precipitation of BSA by adding an equal volume of organic solvent, often successfully used
with conventional HPLC-PDA, was found insufﬁciently robust when novel fused-core HPLC and/or UPLC-MS
methods were used. In this study, three factors (acetonitrile (%), formic acid (%) and boiling time (min)) were
included in the experimental design to determine an optimal and more suitable sample treatment of BSA-
containing FDC solutions. Using a QbD and Derringer desirability (D) approach, combining BSA loss, dilution
factor and variability, we constructed an optimal working space with the edge of failure deﬁned as Do0.9.
The design space is modelled and is conﬁrmed to have an ACN range of 8373% and FA content of 170.25%.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Within the context of in vitro dermal absorption studies, the
choice of receptor ﬂuid is a very important factor with the majorsity. Production and hosting by Elsev
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an Jiaotong University.consideration of the receptor ﬂuid not acting as a rate-limiting
step in the permeation process due to the limited solubility of
the test compound in the medium [1]. During these Franz
diffusion cell (FDC) experiments, usually aqueous-based solu-
tions are used as receiver phase beneath the mounted human or
animal skin section membranes [2]. However, it is well
recognized that for lipophilic compounds this may cause ﬂux
limiting solubility or unstirred layer phenomena which can
obscure the true ﬂux of the drug through the skin. In such cases,
it is advised to use a solubilising additive in order to guarantee
sink conditions throughout the experiment [1–2]. In almost 20%
of recent studies, bovine serum albumin (BSA) was used in aier B.V. All rights reserved.
L. Taevernier et al.28concentration up to 5% (m/V), in which it also contributed to
the in vivo relevance [3–4].
During the FDC studies, samples of receptor ﬂuid are taken at
regular time intervals in order to calculate the cumulative concentra-
tion of permeated drug and its kinetic permeation parameters. Prior to
the chromatographic analysis of the drug, a sample preparation is
required to eliminate the BSA protein and liberate the drug before
HPLC injection. Beside the many existing techniques for deproteinis-
ing samples, the traditional and most simple approach is to add an
equal volume of organic solvent, e.g. acetonitrile. After centrifugation
of the precipitated BSA, an aliquot of the clear supernatant is then
injected into the HPLC system [3–10].
While this approach was often successful for traditional HPLC-
UV analysis, recent experience within our laboratory has indicated
that such a simple sample preparation is insufﬁcient when
switching to more advanced fused-core and/or UPLC-MS systems.
This has led to bad peak shapes with shifted retention times and
increased variability, giving unreliable results, but has also led to
increased column back pressure, insufﬁcient column robustness,
which can also drastically shorten its life span.
The objective of this work was to determine an optimal and
more suitable sample treatment of BSA-containing FDC solutions,
aiming at a BSA precipitation of minimally 95%. We applied an
analytical quality-by-design (QbD) approach, using a multivariate
experimental design to construct a design space.Table 1 Experimental set-up and results.2. Materials and methods
2.1. Reagents
HPLC gradient grade acetonitrile (ACN) was supplied by Fisher
Scientiﬁc (Leicestershire, UK). LC-MS formic acid (FA) was
purchased from Fluka (Buchs, Switzerland). Water was puriﬁed
using an Arium 611 puriﬁcation system (Sartorius, Göttingen,
Germany), resulting in ultrapure water of 18.2 MΩ cm quality.
Phosphate buffered saline (PBS) (pH 7.4; 0.01 M) and Bradford
reagent came from Sigma (St. Louis, MO, USA). BSA used for the
FDC samples was bought from Merck (Darmstadt, Germany),
while the 2 mg/mL BSA protein standard stock for analytical
quantiﬁcation came from Thermo Scientiﬁc (Waltham, MA,
USA).2.2. Experimental design and modelling
In this study, three factors were examined: boiling time (0.25–
3 min), formic acid content (0.5–5%) and acetonitrile content (70–
90%). The main and ﬁrst response, i.e., percentage BSA loss, was
calculated according to the following formula: BSA loss (%)¼ (1–
([BSA]left/[BSA]applied)) 100%, where [BSA]left is the calculated
BSA concentration after sample preparation and [BSA]applied is the-
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Analytical QbD for BSA-containing samples 29theoretical BSA concentration added at the start of the experiment.
Two other responses were also considered, i.e., dilution factor
(DF) deﬁned as DF¼Vtotal/Vsample and the variability expressed as
RSD (in percentage). From these three individual responses, a
global Derringer desirability (D) was calculated.
Previous pilot experiments already indicated that relatively low
ACN levels, i.e., 50% and 60%, resulted in a BSA loss that was
too low to be usable and characterized by an extremely high
variability. Therefore, these levels were excluded from further
experiments, obtaining a model containing all experimental data
available in a justiﬁed region.
Multivariate data-analysis and modelling was performed using
Modde 8.0.2 software (Umetrics, Umea, Sweden). The BSA loss
data, expressed as percentage, as well as dilution factor (DF),
variability (expressed as RSD) and Derringer desirability (D) were
used as dependent variables to ﬁt the most appropriate multiple
linear regression (MLR) model and to construct contour plots.
2.3. Sample preparation
A well-deﬁned volume of FA, ACN and H2O was brought into an
adequate tube according to the established design, with H2O
serving as an adjuvant to match the degrees of freedom. Next,
200 mL of a 3% BSA in PBS solution was added to each tube; this
sample quantity and BSA concentration are normally used in FDCFig. 1 Coefﬁcient plot: different factors and interactions plotted in functi
insigniﬁcant factors and interactions (α¼0.01), which were removed from
factors and interactions.
Table 2 Summary of model ﬁtness for BSA loss %¼–69.39
FAþ42.68 ACNþ0.80 FAACN0.27 ACN2–1601.55.
Performance
indicators
Reference
values [14]
Results of our model
R2 1 0.888 Good ﬁtness of the
data
Q2 40.5 0.794 Excellent
predictability
Model validity 40.25 0.308 Valid model
Reproducibility 40.5 0.959 Excellent
reproducibilityskin studies. Different volumes were thus obtained, resulting in
different dilution factors of the original BSA-containing sample.
All recipients were then thoroughly shaken and vortexed to ensure
complete homogenization. Of each sample solution, a 400 mL
aliquot was transferred to a 0.5 mL Eppendorf tube, after which
the tubes were placed in a boiling water bath for a predetermined
time (Table 1). Immediately thereafter, samples were placed on ice
for 1575 min and centrifuged at a relative centrifugational force
of 20,800 g for 10 min at room temperature. The supernatant was
then subjected to the Bradford protein assay.
2.4. Bradford colorimetric protein assay
Multiple protein assays are available, of which some measure amino
acids and/or small peptides as well, e.g., absorption spectrophotometry
at 280 nm or the colorimetric assay with bicinchoninic acid [11–12].
However, for our purpose, quantiﬁcation of BSA is required and not of
its peptides or amino acids. Therefore, the Bradford assay was used, as
this colorimetric assay determines only proteins with a molecular
weight over 3000 Da. This method is based on an absorbance shift of
the Coomassie Brilliant Blue G-250 dye which is converted from red
to its blue form upon binding to the protein. It is this blue bound form
that is detected at its absorption maximum at 595 nm [13]. In this
study, the Bradford standard 3.1 mL assay protocol was followed as
instructed by the supplier (Appendix A).
For the construction of the calibration curve, a standard solution
series was made ranging between 0.25 mg/mL and 1.4 mg/mL.
Also a blank solution was analyzed using 0.1 mL PBS. A linear
regression model was used to calculate the BSA concentration in
the examined samples.3. Results and discussion
The results of this study are given in Table 1. Simple visual
interpretation of the data already suggests that (i) not only the
amount of ACN, but also FA percentage plays a major part in BSA
precipitation, (ii) at low levels of ACN, the BSA loss is low and
the variability of the results is high and (iii) varying the boiling
time does not signiﬁcantly inﬂuence the BSA loss.on of the percentage BSA loss. The red rectangles denote statistically
the ﬁnal model. The green boxes indicate the signiﬁcant preserved
Fig. 2 Quality-by-design composed desirability functions with three
identiﬁed critical quality attributes (BSA loss, variability in BSA loss
and dilution factor) corresponding with our design space.
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multiple linear regression (MLR) model. The coefﬁcient plot in
Fig. 1 represents the signiﬁcance of all factors and interactions at
α¼0.01. The green boxes indicate the signiﬁcant factors and
interactions, whereas the red boxes denote the insigniﬁcant ones (i.
e., their 99% conﬁdence interval contains zero). The ﬁnal model
was composed by eliminating the statistically irrelevant factors and
interactions and is described by: BSA loss (%)¼–69.39
FAþ42.68 ACNþ0.80 FAACN–0.27 ACN2–1601.55. The
overall summary of ﬁt of this model is presented in Table 2.
When comparing the results obtained for the performance indica-
tors (R2, Q2, model validity and reproducibility) with generally
accepted reference values, this indicates a valid model with
excellent predictability and reproducibility and a good ﬁtness of
the data [14].
If these results are applied on a real-life transdermal Franz
diffusion cell (FDC) study, another critical quality attribute is
deﬁned: the lowest possible volume of ACN should be used in
order to prevent too much sample dilution, leading to a
decreased sensitivity in the assay method. Secondly, the sample
preparation needs to be reproducible, requiring consistent BSA
loss. Three user speciﬁcations are thus deﬁned as analytical
quality attributes: high BSA loss, low dilution factor and low
variability. To determine the optimal working conditions, the
Derringer desirability approach was applied, with the three
desirability functions composed as presented in Fig. 2 [15–17].
The BSA loss was transformed to desirability d1 using an
exponential function. Secondly, the robustness of BSA loss (d2)
was modelled using a descending linear function. The residual
standard deviations (RSDs) on the responses were calculated
describing the variability at that ACN level; ideally, a low RSD
is preferred. The desirability for the dilution factor (d3) was
again described using a descending linear function, where a
dilution factor (DF) of 50 was considered to be undesirable
(d¼0.1) and no dilution, i.e., DF¼1, was most desirable
(d¼1). These three functions were then used to transform our
results into their corresponding d-values and subsequently, the
global Derringer desirability (D) was calculated using the
geometric mean D¼ (d1 d2 d3)1/3.
The obtained d-values are given in Appendix B, and the global
Derringer desirability D was modelled in function of the amount of
ACN and FA, using multiple linear regression: D¼0.18
ACNþ0.074 FA–0.0016 FA2–0.0012 ACN2–0.00092
ACN FA–5.82. Contour plots for the three individual quality
attributes (expressed as d-values) as well as for the global
desirability are shown in Fig. 3. Considering global D-values
Z0.9 as the desired design space, where the results are equally
acceptable for our purposes, two optimal domains (D¼0.9) can be
deﬁned in the contour plots, as visualized in Fig. 3 (red colored
region) and derived from the D-equation given above: (1)
FA44% and (2) FAo2.5%. We have chosen the target point
deﬁned by 83% ACN and 1% FA as the optimal point within our
experimental space. This target value is accepted to be the most
robust condition, i.e., where variations in percentage FA and ACN
do not signiﬁcantly inﬂuence the global D outcome. Moreover,
lower FA percentages are also preferred for operational reasons,
i.e. more appropriate for HPLC systems and prolonged column
lifetime. While both factors are thus confounded with each other,
in practice, these results also allow a more QC-operational
approach as an individual tolerance: 8373% ACN and
170.25% FA.4. Conclusions
It goes without saying that a ‘one size ﬁts all’ approach no longer
has a place in modern analytical chemistry. Building-in quality
should start early on, i.e., at the method development stage. In
contrast to the conventional HPLC-PDA equipment, sample
preparation of samples containing BSA, e.g., Franz diffusion cell
solutions, demands special attention when novel fused core and/or
UPLC-MS equipment is used. We suggested a QbD approach for
sample pretreatment of BSA-containing samples. We have shown
that not only the amount of ACN but also FA percentage plays a
major part in BSA precipitation, while also considering the
dilution effects and the variability in a global Derringer desirability
Fig. 3 Contour plots: d1 (BSA loss), d2 (variability in BSA loss), d3 (dilution factor) and D (global optimum) in function of the amount of ACN
and FA.
Analytical QbD for BSA-containing samples 31(D) response. A well-deﬁned design space was constructed, for
which the target point was derived.Acknowledgments
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